Get the Stockscreener App
2.12
0.95%
0.02
After Hours:
2.10
-0.02
-0.94%
Prokidney Corp stock is traded at $2.12, with a volume of 1.58M.
It is up +0.95% in the last 24 hours and down -33.75% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
1.58M
Relative Volume:
0.80
Market Cap:
$300.08M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.7193
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-8.62%
1M Performance:
-33.75%
6M Performance:
+198.34%
1Y Performance:
+12.77%
1-Day Range:
$2.04
$2.15
1-Week Range:
$2.04
$2.4693
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.12 | 297.25M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney site sells Greensboro site for $6.5M less than it paid for property - The Business Journals
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership - Yahoo Finance
ProKidney Corp. (PROK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How ProKidney Corp. stock benefits from tech adoptionWeekly Volume Report & Smart Money Movement Alerts - newser.com
Will ProKidney Corp. stock beat EPS estimatesMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
What data driven models say about ProKidney Corp.’s futureQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 EndofMonth & Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Recession Risk & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about ProKidney Corp. stock2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
[EFFECT] PROKIDNEY CORP. SEC Filing - Stock Titan
Automated trading signals detected on ProKidney Corp.Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Will ProKidney Corp. stock recover faster than peersDollar Strength & AI Enhanced Trading Alerts - newser.com
Greensboro ProKidney site sells for $19.1M - Winston-Salem Journal
What to expect from ProKidney Corp. in the next 30 daysQuarterly Investment Review & Daily Growth Stock Tips - newser.com
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts - MarketBeat
Brian Jg Pereira Sells 255,026 Shares of ProKidney (NASDAQ:PROK) Stock - MarketBeat
Insider Selling: ProKidney (NASDAQ:PROK) Director Sells 502,136 Shares of Stock - MarketBeat
Will ProKidney Corp. stock go up soonWeekly Gains Summary & Breakout Confirmation Trade Signals - newser.com
What candlestick patterns are forming on ProKidney Corp.2025 Historical Comparison & Stepwise Trade Signal Implementation - newser.com
Is ProKidney Corp. stock poised for growthJuly 2025 Spike Watch & Reliable Price Action Trade Plans - newser.com
ProKidney Independent Director Brian Jude Pereira Sells 100% Of Holding - simplywall.st
Visual analytics tools that track ProKidney Corp. performance2025 Retail Activity & AI Driven Price Forecasts - newser.com
Heatmap analysis for ProKidney Corp. and competitorsInflation Watch & Risk Adjusted Swing Trade Ideas - newser.com
How ProKidney Corp. stock performs in stagflationMarket Risk Analysis & High Accuracy Swing Entry Alerts - newser.com
ProKidney (NASDAQ:PROK) Shares Down 14.4%Time to Sell? - MarketBeat
Dir Pereira Sells 757,162 ($1.9M) Of ProKidney Corp [PROK] - TradingView
Tangible book value per share of ProKidney Corp. Class A – BMV:PROK - TradingView
Published on: 2025-11-13 04:33:50 - newser.com
Dir Pereira Files To Sell 675,234 Of ProKidney Corp [PROK] - TradingView
ProKidney’s Autologous Cell Therapy for CKD and Diabetes Advances to Phase III - Inside Precision Medicine
ProKidney at Guggenheim Conference: Strategic Advances in Kidney Treatment By Investing.com - Investing.com Nigeria
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):